<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730037</url>
  </required_header>
  <id_info>
    <org_study_id>CTR225-01</org_study_id>
    <nct_id>NCT04730037</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)</brief_title>
  <official_title>An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-group Study of Evaluate the Efficacy and Safety of Edoxaban Versus Warfarin (Vitamin K Antagonist) in Subjects With Chronic Thromboembolic Pulmonary Hypertension Taking Warfarin (Vitamin K Antagonist) at Baseline: KABUKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is phase III trial to evaluate whether edoxaban, a direct factor Xa inhibitor, is&#xD;
      noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary&#xD;
      hypertension (CTEPH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of 1-year resting PVR to baseline resting PVR</measure>
    <time_frame>Week 48 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of cases with CTEPH exacerbation events</measure>
    <time_frame>Throughout the study duration(up to week48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in distance of 6-minute walking test</measure>
    <time_frame>Week16, 32, 48 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in WHO functional classification class</measure>
    <time_frame>Week16, 32, 48 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NT-proBNP concentration</measure>
    <time_frame>Week16, 32, 48 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cases with clinically significant bleeding</measure>
    <time_frame>Throughout the study duration(up to week48)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>CTEPH</condition>
  <arm_group>
    <arm_group_label>Edoxaban group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications</description>
    <arm_group_label>Edoxaban group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin Potassium</intervention_name>
    <description>- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)</description>
    <arm_group_label>Warfarin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin Potassium placebo</intervention_name>
    <description>- Warfarin K 1 mg placebo tablets once daily</description>
    <arm_group_label>Edoxaban group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban placebo</intervention_name>
    <description>- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications</description>
    <arm_group_label>Warfarin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient who once* diagnosed with CTEPH based on imaging study (VQ scan, CT pulmonary&#xD;
             angiogram) and hemodynamic criteria (MPAP &gt;=25 mmHg and PAWP =&lt; 15 mmHg). *Patients&#xD;
             treated with PEA, BPA, or vasodilators, who do not meet hemodynamic criteria at the&#xD;
             registration, are eligible.&#xD;
&#xD;
          2. Patients who are not planned to require increased / changed / discontinuation of PEA,&#xD;
             BPA, or pulmonary vasodilators within 12months&#xD;
&#xD;
          3. Stable administration of vitamin K antagonists&#xD;
&#xD;
          4. WHO functional class I-III&#xD;
&#xD;
          5. Patients who meet A) B)and C) by 90 days prior to baseline. A)No addition, reduction,&#xD;
             or change of endothelin antagonists, soluble guanylate cyclase stimulants,&#xD;
             phosphodiesterase-5 inhibitors, prostacyclin, and its derivatives, or calcium&#xD;
             antagonists. B)Appropriate anticoagulants have been continued. C)No BPA has been done.&#xD;
&#xD;
          6. Patients who have not undergone PEA from 180 days prior to baseline right heart&#xD;
             catheterization to the start date of study drug administration&#xD;
&#xD;
          7. Patients with a 6-minute walking distance &gt;=150m&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe lung disease (FEV1.0/FVC &lt; 60% or %TLC &lt; 60%)&#xD;
&#xD;
          2. Patients with acute or chronic disabilities that interfere with clinical trial&#xD;
             requirements&#xD;
&#xD;
          3. Patients with acute symptomatic PE within 180 days prior to the start of study drug&#xD;
             administration&#xD;
&#xD;
          4. Patients with congenital heart disease who have not undergone radical surgery&#xD;
&#xD;
          5. Patients who cannot provide informed consent due to mental disorders, dementia, or&#xD;
             other illnesses&#xD;
&#xD;
          6. Patients with advanced cancer&#xD;
&#xD;
          7. Patients with a life expectancy of less than 1 year&#xD;
&#xD;
          8. Patients with active hemorrhagic lesions&#xD;
&#xD;
          9. Patients with comorbidities requiring vitamin K antagonist&#xD;
&#xD;
         10. Patients receiving other study drug within 30 days prior to randomization&#xD;
&#xD;
         11. Patients with renal dysfunction (Ccr 15 mL/min)&#xD;
&#xD;
         12. Patients with liver dysfunction (Child-Pugh B or C)&#xD;
&#xD;
         13. Females of reproductive age not using an acceptable form of&#xD;
             contraception/Pregnant/Breastfeeding&#xD;
&#xD;
         14. Patients contraindicated for edoxaban or warfarin&#xD;
&#xD;
         15. Patients with hypersensitivity to any of the drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kohtaro Abe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kazuya Hosokawa</last_name>
    <phone>+81-92-642-5360</phone>
    <email>hosokawa.kazuya.712@m.kyushu-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuko Kobayakawa</last_name>
    <phone>+81-92-642-5110</phone>
    <email>kobayakawa.yuko.527@m.kyushu-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuya Hosokawa</last_name>
      <phone>+81-092-642-5360</phone>
      <email>hosokawa.kazuya.712@m.kyushu-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Hosokawa K, Abe K, Tsutsui H. Use of direct oral anticoagulants prevents increase in pulmonary vascular resistance and incidence of clinical worsening in patients with chronic thromboembolic pulmonary hypertension. Thromb Res. 2019 Aug;180:43-46. doi: 10.1016/j.thromres.2019.05.018. Epub 2019 May 31.</citation>
    <PMID>31200342</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyushu University</investigator_affiliation>
    <investigator_full_name>Kohtaro Abe</investigator_full_name>
    <investigator_title>Department of Cardiovascular Medicine, Faculty of Medical Sciences</investigator_title>
  </responsible_party>
  <keyword>Edoxaban</keyword>
  <keyword>DOAC</keyword>
  <keyword>Wafrarin</keyword>
  <keyword>Anticoagulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

